Aura Rusu

Prof. Dr. Aura Rusu

Pharmaceutical and Therapeutical Chemistry, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania, Târgu-Mureş, Mureş, Romania
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Aura RusuAura Rusu
Aura Rusu
Ioana-Maria StroiaIoana-Maria Stroia
Ioana-Maria Stroia
Livia UncuLivia Uncu
Livia Uncu
Gabriel HancuGabriel Hancu
Gabriel Hancu
Five-membered heterocycles are essential structural components in various antibacterial drugs; the physicochemical properties of a five-membered heterocycle can play a crucial role in determining the biological activity of an antibacterial drug. These properties can affect the drug’s activity spectrum, potency, and pharmacokinetic and toxicological properties. Using scientific databases, we identified and discussed the antibacterials used in therapy, containing five-membered heterocycles in their molecular structure. The identified five-membered heterocycles used in antibacterial design contain one to four heteroatoms (nitrogen, oxygen, and sulfur). Antibacterials containing five-membered heterocycles were discussed, highlighting the biological properties imprinted by the targeted heterocycle. In some antibacterials, heterocycles with five atoms are pharmacophores responsible for their specific antibacterial activity. As pharmacophores, these heterocycles help design new medicinal molecules, improving their potency and selectivity and comprehending the structure-activity relationship of antibiotics. Unfortunately, particular heterocycles can also affect the drug’s potential toxicity. The review extensively presents the most successful five-atom heterocycles used to design antibacterial essential medicines. Understanding and optimizing the intrinsic characteristics of a five-membered heterocycle can help the development of antibacterial drugs with improved activity, pharmacokinetic profile, and safety.

5 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Aura RusuAura Rusu
Aura Rusu
EBEmanuela Lorena Buta
Emanuela Lorena Buta
The tetracycline antibiotic class has acquired new valuable members due to the optimisation of the chemical structure. The first modern tetracycline introduced into therapy was tigecycline, followed by omadacycline, eravacycline, and sarecycline (the third generation). Structural and physicochemical key elements which led to the discovery of modern tetracyclines are approached. Thus, several chemical subgroups are distinguished, such as glycylcyclines, aminomethylcyclines, and fluorocyclines, which have excellent development potential. The antibacterial spectrum comprises several resistant bacteria, including those resistant to old tetracyclines. Sarecycline, a narrow-spectrum tetracycline, is notable for being very effective against Cutinebacterium acnes. The mechanism of antibacterial action from the perspective of the new compound is approached. Several severe bacterial infections are treated with tigecycline, omadacycline, and eravacycline (with parenteral or oral formulations). In addition, sarecycline is very useful in treating acne vulgaris. Tetracyclines also have other non-antibiotic properties that require in-depth studies, such as the anti-inflammatory effect effect of sarecycline. The main side effects of modern tetracyclines are described in accordance with published clinical studies. Undoubtedly, this class of antibiotics continues to arouse the interest of researchers. As a result, new derivatives are developed and studied primarily for the antibiotic effect and other biological effects.

1 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Aura RusuAura Rusu
Aura Rusu
EAEliza Mihaela Arbănași
Eliza Mihaela Arbănași
EAEliza Mihaela Arbănași
Eliza Mihaela Arbănași
Valentina UivarosiValentina Uivarosi
Valentina Uivarosi
Antibacterial fluoroquinolones (FQs) are frequently used in treating infections. However, the value of FQs is debatable due to their association with severe adverse effects (AEs). The Food and Drug Administration (FDA) issued safety warnings concerning their side-effects in 2008, followed by the European Medicine Agency (EMA) and regulatory authorities from other countries. Severe AEs associated with some FQs have been reported, leading to their withdrawal from the market. New systemic FQs have been recently approved. The FDA and EMA approved delafloxacin. Additionally, lascufloxacin, levonadifloxacin, nemonoxacin, sitafloxacin, and zabofloxacin were approved in their origin countries. The relevant AEs of FQs and their mechanisms of occurrence have been approached. New systemic FQs present potent antibacterial activity against many resistant bacteria (including resistance to FQs). Generally, in clinical studies, the new FQs were well-tolerated with mild or moderate AEs. All the new FQs approved in the origin countries require more clinical studies to meet FDA or EMA requirements. Post-marketing surveillance will confirm or infirm the known safety profile of these new antibacterial drugs. The main AEs of the FQs class were addressed, highlighting the existing data for the recently approved ones. In addition, the general management of AEs when they occur and the rational use and caution of modern FQs were outlined.

22 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ILIoana-Andreea Lungu
Ioana-Andreea Lungu
OMOctavia-Laura Moldovan
Octavia-Laura Moldovan
VBVictoria Biriș
Victoria Biriș
Aura RusuAura Rusu
Aura Rusu
The emergence of bacterial resistance has motivated researchers to discover new antibacterial agents. Nowadays, fluoroquinolones keep their status as one of the essential classes of antibacterial agents. The new generations of fluoroquinolones are valuable therapeutic tools with a spectrum of activity, including Gram-positive, Gram-negative, and atypical bacteria. This review article surveys the design of fluoroquinolone hybrids with other antibacterial agents or active compounds and underlines the new hybrids’ antibacterial properties. Antibiotic fluoroquinolone hybrids have several advantages over combined antibiotic therapy. Thus, some challenges related to joining two different molecules are under study. Structurally, the obtained hybrids may contain a cleavable or non-cleavable linker, an essential element for their pharmacokinetic properties and mechanism of action. The design of hybrids seems to provide promising antibacterial agents helpful in the fight against more virulent and resistant strains. These hybrid structures have proven superior antibacterial activity and less susceptibility to bacterial resistance than the component molecules. In addition, fluoroquinolone hybrids have demonstrated other biological effects such as anti-HIV, antifungal, antiplasmodic/antimalarial, and antitumor activity. Many fluoroquinolone hybrids are in various phases of clinical trials, raising hopes that new antibacterial agents will be approved shortly.

28 August 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Aura RusuAura Rusu
Aura Rusu
Corneliu TanaseCorneliu Tanase
Corneliu Tanase
GPGeorgiana-Andreea Pascu
Georgiana-Andreea Pascu
NTNicoleta Todoran
Nicoleta Todoran
Adapalene (ADP) is a representative of the third retinoids generation and successfully used in first-line acne treatment. ADP binds to retinoic acid nuclear receptors. The comedolytic, anti-inflammatory, antiproliferative, and immunomodulatory are the known ADP effects. Its safety profile is an advantage over other retinoids. ADP recently was found to be effective in the treatment of several dermatological diseases and photoaging besides the utility in the treatment of acne vulgaris. New biological effects of adapalene with therapeutic potential are highlighted in this review paper. Thus, adapalene could be a valuable therapeutic drug into the treatment of several types of cancer. Additionally, some neurodegenerative diseases could be treated with a suitable formulation for intravenous administration. The antibacterial activity against methicillin-resistant Staphylococcus aureus of an analogue of ADP has been proven. In different therapeutic schemes, ADP is more effective in combination with other active substances. New topical combinations with adapalene include ketoconazole (antifungal), mometasone furoate (anti-inflammatory corticosteroid), nadifloxacin (fluoroquinolone), and alfa and beta hydroxy acids. Combination with oral drugs is a new trend that enhances the properties of topical formulations with adapalene. Several studies have investigated the effects of ADP in co-administration with azithromycin, doxycycline, faropenem, isotretinoin, and valganciclovir. Innovative formulations of ADP also aim to achieve a better bioavailability, increased efficacy, and reduced side effects. In this review, we have highlighted the current studies on adapalene regarding biological effects useful in various treatment types. Adapalene has not been exploited yet to its full biological potential.

13 December 2021 in Materials
Verified
Journal Article
Open access
PDF file
LBLavinia Berta
Lavinia Berta
NCNastaca Alina Coman
Nastaca Alina Coman
Aura RusuAura Rusu
Aura Rusu
Corneliu TanaseCorneliu Tanase
Corneliu Tanase
The study of bimetallic nanoparticles (BNPs) has constantly been expanding, especially in the last decade. The biosynthesis of BNPs mediated by natural extracts is simple, low-cost, and safe for the environment. Plant extracts contain phenolic compounds that act as reducing agents (flavonoids, terpenoids, tannins, and alkaloids) and stabilising ligands moieties (carbonyl, carboxyl, and amine groups), useful in the green synthesis of nanoparticles (NPs), and are free of toxic by-products. Noble bimetallic NPs (containing silver, gold, platinum, and palladium) have potential for biomedical applications due to their safety, stability in the biological environment, and low toxicity. They substantially impact human health (applications in medicine and pharmacy) due to the proven biological effects (catalytic, antioxidant, antibacterial, antidiabetic, antitumor, hepatoprotective, and regenerative activity). To the best of our knowledge, there are no review papers in the literature on the synthesis and characterisation of plant-mediated BNPs and their pharmacological potential. Thus, an effort has been made to provide a clear perspective on the synthesis of BNPs and the antioxidant, antibacterial, anticancer, antidiabetic, and size/shape-dependent applications of BNPs. Furthermore, we discussed the factors that influence BNPs biosyntheses such as pH, temperature, time, metal ion concentration, and plant extract.